PBM — Psyence Biomedical Income Statement
0.000.00%
Last trade - 00:00- $1.96m
- $8.89m
Annual income statement for Psyence Biomedical, fiscal year end - March 31st, USD millions except per share, conversion factor applied.
2022 March 31st | 2023 March 31st | 2024 March 31st | |
|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS |
| Standards: | IFRS | IFRS | IFRS |
| Status: | fx Final | Final | Final |
| Total Revenue | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||
| Research And Development | |||
| Depreciation and Amortization | |||
| Unusual Expense / Income | |||
| Total Operating Expenses | 1.85 | 3.23 | 46.4 |
| Operating Profit | -1.85 | -3.23 | -46.4 |
| Total Net Non Operating Interest Income / Expense | |||
| Other Net Non Operating Costs | |||
| Net Income Before Taxes | -1.85 | -3.21 | -51.2 |
| Net Income After Taxes | -1.85 | -3.21 | -51.2 |
| Net Income Before Extraordinary Items | |||
| Net Income | -1.85 | -3.21 | -51.2 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||
| Income Available to Common Shareholders Including Extraordinary Items | |||
| Diluted Net Income | -1.85 | -3.21 | -51.2 |
| Diluted Weighted Average Shares | |||
| Basic EPS Including Extraordinary Items | |||
| Diluted EPS Including Extraordinary Items | |||
| Diluted EPS Excluding Extraordinary Items | |||
| Normalised Income Before Taxes | |||
| Normalised Income After Taxes | |||
| Normalised Income Available to Common Shareholders | |||
| Diluted Normalised EPS | -10.4 | -18 | -42 |
| Dividends per Share |